ImmunoGen Jumps Most in 25 Years on Cancer Drug Results
This article is for subscribers only.
ImmunoGen Inc. rose 72 percent after releasing positive data on its ovarian cancer drug at the American Society of Clinical Oncology annual meeting Saturday in Chicago.
The Waltham, Massachussetts-based company’s mirvetuximab soravtansine, a treatment for patients with ovarian cancer who became resistant to other drugs, had a 53 percent response rate, according to a company statement. Data from 17 patients was reviewed in the Phase I study, whose main purpose is to tell if drugs are safe.